Leptospermum scoparium

Other Names

árbol de té Neozelandésbroom tea-treebroom teatreecrimson tea bushkahikātoakahikatoakatoakātoaLeptospermum bullatumLeptospermum floribundumLeptospermum humifusumLeptospermum linifoliumLeptospermum multiflorumLeptospermum nichollsiiLeptospermum obliquumLeptospermum oxycedrusLeptospermum pungensLeptospermum scoparium subsp. roseumLeptospermum scoparium subsp. rubrum-pygmaeumLeptospermum scoparium var. bullatumLeptospermum scoparium var. chapmanniiLeptospermum scoparium var. confertifoliumLeptospermum scoparium var. eximeaLeptospermum scoparium var. forsteriLeptospermum scoparium var. incanumLeptospermum scoparium var. linearifoliumLeptospermum scoparium var. linifoliumLeptospermum scoparium var. myrtifoliumLeptospermum scoparium var. nichollsiiLeptospermum scoparium var. parvumLeptospermum scoparium var. prostratumLeptospermum scoparium var. sericeumLeptospermum scoparium var. vulgaremanukamānukamānuka myrtlemanuka myrtleMelaleuca scopariaMelaleuca tenuifoliaNew Zealand tea treeNew Zealand teatreepataPhiladelphus aromaticusPhiladelphus floribundusPhiladelphus scopariusPhiladelphus scoparius var. linifoliusPhiladelphus scoparius var. myrtifoliusrauirirauwiritaramānukatea tree松红梅澳洲茶

Synopsis

Leptospermum scoparium (Mānuka): A Comprehensive Reference

1. Identity and Botanical Overview

Scientific Name and Taxonomy

Leptospermum scoparium (J.R. Forst. & G. Forst.) is a species of flowering plant in the myrtle family Myrtaceae, native to New Zealand (including the Chatham Islands) and south-east Australia. It is commonly known as mānuka, and also by the alternative Māori name kahikātoa. Other common synonyms include Manuka myrtle, New Zealand tea tree, and broom tea-tree. The Latin specific epithet scoparium means "like broom," referring to Northern Hemisphere genera such as Genista and Cytisus, to which it is only distantly related.

Botanical Description and Habitat

L. scoparium is the only Leptospermum species native to New Zealand. Its size ranges from a creeping plant to a small tree of up to 8 m in height and is widely distributed in various climatic and altitudinal zones in New Zealand. Physical characteristics such as flower and leaf color, leaf size and shape, branching habit, and foliage density vary considerably among populations. All forms of this species are unified by their sharp-tipped leaves, large, solitary white or pink-flushed flowers with distinctive short, dark red stamens, and persistent greyish-white nut-like capsules. Mānuka is a prolific shrub-type tree and is often one of the first species to regenerate on cleared land.

Biogeographic Origin

Evidence suggests that L. scoparium originated in Australia before the onset of the Miocene aridity and moved as a result of long-distance dispersal events to New Zealand from eastern Australia sometime during the last 20 million years. Cyclones and other wind activity are most likely responsible for transporting seeds long distances. Supporters cite evidence that the genus Leptospermum arose under conditions where frequent forest fires were common (i.e., in Australia, not temperate New Zealand), because they possess fire-adaptive traits like serotiny and storage lignotubers.

Common Preparations and Commercial Forms

L. scoparium gives rise to several distinct commercial preparations used as dietary supplements and natural health products:

Mānuka honey: Bees produce mānuka honey from the plant's nectar. It is the most commercially significant and scientifically studied product derived from L. scoparium.
Mānuka essential oil: Mānuka oil (CAS 219828-87-2) is a volatile essential oil derived from the foliage, bark, and seeds of Leptospermum scoparium. A clear liquid with an aromatic odor is produced by a steam distillation process from plants harvested mostly in autumn, summer, and spring, with a yield ranging from 0.2–1%, depending on seasonal and geographical factors.
Leaf and bark extracts: Various preparations of the gum, sap, seed pods, leaves, bark, and flowers of mānuka have been used both externally and internally to treat many conditions.
Medical-grade honey dressings: The honey used to treat wounds is medical-grade honey, specially sterilized and prepared as a dressing.

2. Traditional and Historical Use

Rongoā Māori (Māori Traditional Medicine)

From the earliest human habitation of New Zealand by the Māori people around 800 to 1000 years ago, the mānuka plant (Leptospermum scoparium) was known to have special medicinal and therapeutic properties. In traditional Māori culture, mānuka was used for a wide variety of purposes, including as a building material, for items such as combs, paddles, and digging sticks, to construct eel weirs, for weaponry, and to construct palisade walls of pā. The plant also had uses in traditional rongoā medicine, with infusions being made from leaves, or by collecting mānuka gum.

Mānuka was historically used in New Zealand by Māori and later European settlers for purposes including the treatment of respiratory ailments, burns, dandruff, dysentery, fever, and indigestion, as well as being drunk as a type of tea.

The hard, red wood of mānuka was widely used by Māori for everything from paddles, weapons, spade blades, bird spears, and mauls to house building. Its bark was used for making water containers.

Use as a Beverage and Tonic

The leaves of mānuka served as a very common substitute for tea. The plant produces a saccharine substance like manna called Pia and Tohika, which is eaten. As a refreshing tea it was recorded to be emetic when brewed strong. An infusion of mānuka boughs was much drunk by whalers. Captain Cook used it as a tea substitute on his first voyage and, on his second voyage, combined it with rimu to make a spruce beer; it was noted to have anti-scorbutic properties.

Indigenous Australian Use

Mānuka (Leptospermum scoparium), also known as kahikatoa, red mānuka, and tea tree, belongs to the Myrtaceae plant family and is found throughout New Zealand and Australia. Commonly grouped under "tea trees," these species have been used by the Māori, the Aboriginals, and early European settlers as topical preparations for wounds, cuts, sores, and skin diseases, and as inhalations for colds and fevers.

3. Key Constituents and Active Compounds

Mānuka Essential Oil: Chemical Profile

The major components of commercial New Zealand essential oils of Leptospermum scoparium (manuka) have been identified. In the manuka oil, monoterpenes are present at low levels (≤3%). Sesquiterpene hydrocarbons are predominant (≥60%) and include groups possessing cubebene/copaene, elemene, gurjunene/aromadendrene, farnesene/caryophyllene, selinene, calamenene, and cadinene skeletons. Oxygenated sesquiterpenes and triketones are present at ≤30%.

The major components of commercially available mānuka oils are reported to be leptospermone (0.8–19.4%), calamenene (2.5–18.5%), δ-cadinene (0.9–6.9%), cadina-1,4-diene (0.1–5.9%), flavesone (0.7–5.8%), cadina-3,5-diene (3.0–10.0%), α-copaene (4.3–6.5%), and α-selinene (1.3–5.0%).

A large number of studies have examined the constituents of mānuka oil, which vary depending on the source of the oil as well as the plant chemotype and season of collection. Overall, 100 components were identified from 16 commercial samples of mānuka oil, of which 51 components made up 95% of the content.

β-Triketones: The Primary Antimicrobial Class

The antimicrobial activity of mānuka oil has been specifically associated with a fraction containing three major and three trace triketones, two of the latter being previously unreported. High concentrations of volatile β-triketones are characteristic compounds and the main antibacterial component in its essential oils. Key members of this class include leptospermone, isoleptospermone, flavesone, and grandiflorone. The major antibacterial component grandiflorone has been identified, along with 20 β-triketones, flavonoids, and phloroglucinol derivatives.

Geographic and Chemotype Variation

The triketone chemotype of mānuka is commercially important because of its antimicrobial activity. Oils from 36 individual plants on the East Cape of New Zealand all showed similar high triketone contents (>20% total triketones) with little seasonal variation. Analyses of oils from 261 individual mānuka plants collected from 87 sites throughout New Zealand showed that the high triketone chemotype was localized on the East Cape, although oils with triketone levels up to 20% were found in the Marlborough Sounds area of the South Island.

Samples from L. scoparium grown in Australia had higher monoterpene levels and almost no triketones compared to those from New Zealand.

Flavonoids and CNS-Relevant Compounds

The New Zealand Myrtacea Leptospermum scoparium Forst. contains lipophilic flavonoids which interact specifically with benzodiazepine receptors. Research identified a specific novel compound: 2,5-dihydroxy-7-methoxy-6,8-dimethylflavan-3-one, a novel flavonoid from Leptospermum scoparium, demonstrated in vitro affinity to the benzodiazepine binding site of the GABA-A receptor–chloride channel complex.

Mānuka Honey: Bioactive Compounds

The pronounced antibacterial activity of mānuka honey is due, at least in part, to reactive methylglyoxal (MG). The concentration of MG in mānuka honeys is up to 100-fold higher than in conventional honeys. The UMF (Unique Mānuka Factor) mark reflects the quantity of mānuka key markers—leptosperin, DHA (dihydroxyacetone), and MGO (methylglyoxal).

Additional bioactive components of mānuka honey include:

Hydrogen peroxide: Hydrogen peroxide is slowly released from honey placed on a wound through the interaction of wound exudates with the honey's inherent glucose oxidase. This hydrogen peroxide is in sufficient concentration to be antibacterial, yet dilute enough to be nontoxic, while promoting fibroblast proliferation and angiogenesis.
Lepteridine: A compound identified in mānuka honey, later named lepteridine (3,6,7-trimethyllumazine), was only observed in mānuka honeys and could potentially serve as a biomarker for genuine mānuka honey.
Phenolic compounds: Mānuka honey offers antibacterial, anti-inflammatory, antioxidant, and tissue-regenerative properties through methylglyoxal, phenolic compounds, high sugar content, and low pH.

Honey pH and Osmolarity

Honey has a high osmolarity and a high sugar content, the combination of which has been shown to inhibit microbial growth. Mānuka honey is also known to have a relatively low pH (3.5–4.5), which, in addition to inhibiting microbial growth, stimulates the bactericidal actions of macrophages, and in chronic wounds reduces protease activity, increases fibroblast activity, and increases oxygenation.

4. Mechanisms of Action

Antimicrobial Mechanisms

Mānuka products are associated with multiple, overlapping antimicrobial mechanisms. The honey works through multiple mechanisms: it creates an acidic environment unfavorable to bacterial growth, draws moisture away from bacterial cells through osmosis, and the MGO compound directly disrupts bacterial proteins. This multi-pronged approach makes it difficult for bacteria to develop resistance.

While MGO exerts substantial biocidal properties, one study further showed that MGO performed better when incorporated into honey solutions than on its own, suggesting that MGO partially contributes to mānuka honey's antibiofilm activity, but the full effects come from a combination of its complex composition.

Anti-Inflammatory Mechanisms

Mānuka honey has been documented to decrease the production of inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, and IL-6. At the molecular level in the gastrointestinal context, H. pylori induced NF-κB and AP-1 DNA-binding activity in gastric epithelial cells. Mānuka honey inhibited H. pylori-induced NF-κB and AP-1 in a time- and dose-dependent manner, with maximum inhibition observed at concentrations of 20% at 1–2 hours. Honey also prevented H. pylori-induced degradation of IκB-α protein and downregulated COX-2 protein levels, suggesting it exerts its inhibitory effects by inhibiting NF-κB and AP-1 activation and downregulation of COX-2 expression.

Wound-Healing Mechanisms

The wound-healing properties of mānuka honey are multifactorial. Mānuka honey demonstrates broad-spectrum antimicrobial and antibiofilm effects, supports non-traumatic debridement, and modulates inflammation to promote granulation and re-epithelialisation.

CNS / GABA-A Receptor Interaction

Lipophilic flavonoids from L. scoparium interact specifically with benzodiazepine receptors. From locomotion studies with rats, an in vivo sedating, possibly even anxiolytic effect of the dry extract of the tincture prepared from L. scoparium by use of 70% ethanol was concluded. At doses of 50 mg and 250 mg of the dry extract per kg body weight, an unequivocal but not linear dose-activity relationship in respect to the moving activities of the animals was determined.

5. Scientific Evidence by Area of Use

5.1 Wound Healing and Tissue Repair

Evidence strength: Moderate for burns and partial-thickness wounds (medical-grade honey); preliminary to moderate for chronic wounds.

The findings of animal studies and several randomized clinical trials involving more than 2,000 participants have provided compelling evidence that honey can accelerate wound healing. On the other hand, the quality of reported trials is variable, and evidence to date supports honey only as a treatment of mild-to-moderate superficial and partial thickness burns. Authors of a recent systematic review assert that there is insufficient evidence to guide clinical practice for other wound types.

Mānuka honey demonstrates broad-spectrum antimicrobial and antibiofilm effects, supports non-traumatic debridement, and modulates inflammation to promote granulation and re-epithelialisation. Randomised controlled trials in venous leg ulcers reported that patients receiving conventional therapy had an average wound area reduction of just 8.4% at 24 weeks, compared to 59.6% with advanced treatment.

A retrospective clinical study examined mānuka honey's effect on chronic wounds: a retrospective clinical study of fifteen patients with chronic non-healing extraoral wounds documented complete wound epithelialisation by week four, with average wound depth decreasing from 5.72 mm to 0.88 mm — a statistically significant outcome — and no reported adverse effects throughout the four-week treatment course.

A major limitation in interpreting wound-healing data is the potency of the honey used. Reviews caution that variability between honeys matters: potency ratings (UMF/MGO) and laboratory sterilisation distinguish medical-grade products from pantry honey.

5.2 Antimicrobial Activity Against Antibiotic-Resistant Organisms

Evidence strength: Strong in vitro; promising but limited clinical data.

Honey has been used as a topical wound treatment for millennia and more recently has been formulated into a series of medical-grade honeys for use primarily for wound and burn treatment. A systematic review examined the effectiveness of differing honeys as antimicrobial treatments against a variety of multidrug-resistant (MDR) bacterial species.

Mānuka honey exhibited antimicrobial activity against a spectrum of MDR and non-MDR bacterial organisms isolated from wound sites, with greater potency against staphylococcal organisms compared to gram-negative bacteria.

Synergistic action between piperacillin and methylglyoxal (an antibacterial component characteristically found in mānuka honey) was demonstrated by disc diffusion and chequerboard experiments against MDR clinical isolates of P. aeruginosa. Synergistic combinations of methylglyoxal with carbenicillin and with amikacin were also noted. Furthermore, synergy between oxacillin and mānuka honey in the inhibition of MRSA has been reported, suggesting mānuka honey offers real potential in providing novel synergistic combinations with antibiotics for treating wound infections of MDR bacteria.

Regarding biofilm-forming bacteria at a food-safety level: the activity of mānuka (L. scoparium) essential oil on biofilms of foodborne Listeria monocytogenes and Staphylococcus aureus has been studied, with seven strains of each being tested.

5.3 Anti-Biofilm Activity

Evidence strength: Good in vitro; insufficient human clinical data.

Honey has a bactericidal effect against wound pathogens grown in the laboratory as biofilms. Biofilms of S. aureus and P. aeruginosa exposed to honey were inhibited in vitro. Methylglyoxal has been implicated in the inhibition of biofilms, and is the unique compound in the honey responsible for some of its potent antimicrobial properties.

5.4 Gastrointestinal Applications — Helicobacter pylori and Gastric Ulcers

Evidence strength: In vitro and animal data; human clinical evidence is preliminary and lacks large trials.

A foundational laboratory study published in PMC found that the finding that Helicobacter pylori is probably the causative agent in many cases of dyspepsia raised the possibility that the therapeutic action of honey may be due to its antibacterial properties. All five clinical isolates tested were sensitive to a 20% (v/v) solution of mānuka honey in an agar well diffusion assay. Assessment of the minimum inhibitory concentration showed that all seven isolates tested had visible growth over 72 hours prevented completely by the presence of 5% (v/v) honey.

In a rat model study: the objective was to evaluate the use of mānuka honey in the treatment of acetic acid-induced chronic gastric ulcers in rats. Treatment with mānuka honey significantly reduced the ulcer index and maintained the glycoprotein content. It also reduced the mucosal myeloperoxidase activity, lipid peroxidation (MDA), and the inflammatory cytokines TNF-α, IL-1β, and IL-6 compared to the untreated control group. Honey-treated groups showed significant increases in enzymatic (GPx and SOD) and nonenzymatic (GSH) antioxidants, besides levels of the anti-inflammatory cytokine IL-10. This study was conducted in animals; human clinical data in this area remain very limited.

A feasibility randomized controlled trial for functional dyspepsia in humans has been registered, noting that mānuka honey has unique bioactive properties, including the ability to decrease production of inflammatory cytokines such as TNF-α, IL-1β, and IL-6. However, this represents a protocol publication, not published outcomes data.

5.5 Radiotherapy-Induced Oral Mucositis

Evidence strength: Small, preliminary randomized controlled trials; insufficient for guidelines.

A study evaluated the effects of an essential oil mouthwash on radiation-induced mucositis of the oropharyngeal area during treatment for head and neck cancers. Nineteen adult patients completed the randomized placebo-controlled trial, which involved the use of a gargle containing 2 drops of a 1:1 mix of the essential oils of mānuka (Leptospermum scoparium) and kānuka (Kunzea ericoides) in water. Those in the essential oil gargle group were observed to have a delayed onset of mucositis and reduced pain and oral symptoms relative to placebo (gargling with water) and the "usual care" groups. In addition, those in the essential oil group were seen to have less weight loss (1% loss) than the other two groups (control 2.5%, placebo 4.5%). However, a significant limitation in this study was the small sample size.

No guideline was possible due to insufficient evidence. A double-blind, placebo-controlled, randomized trial of active mānuka honey and standard oral care for radiation-induced oral mucositis was subsequently conducted and published in the British Journal of Oral and Maxillofacial Surgery (Bardy et al., 2012), further investigating this application.

5.6 Anxiolytic / Sedative Properties

Evidence strength: Preliminary animal evidence only; no human clinical trials available.

From locomotion studies with rats, an in vivo sedating, possibly even anxiolytic, effect of the dry extract of the tincture prepared from Leptospermum scoparium using 70% ethanol was concluded. At doses of 50 mg and 250 mg of the dry extract per kg of body weight, an unequivocal but not linear dose-activity relationship in respect to the moving activities of the animals was determined. At a higher application of 500 mg extract per kg body weight, only a negligible reduction of moving activity was found relative to a control group. It was supposed that at higher doses, activating compounds of the extract come to the fore pharmacologically, neutralizing the primarily sedating effect. This evidence is entirely preclinical and has not been replicated in human studies.

5.7 Antiviral Activity

Evidence strength: In vitro only.

Virucidal activity of a β-triketone-rich essential oil of Leptospermum scoparium (mānuka oil) has been investigated against HSV-1 and HSV-2 in cell culture (Planta Med., 2005:71:1123–1127). This evidence is limited to cell culture studies and has not been extended to human clinical trials.

6. Body Systems and Health Areas Associated with Leptospermum scoparium

Integumentary system (skin and wound healing): The most clinically supported area; mānuka honey and essential oil are both used topically for wounds, burns, ulcers, and skin infections.
Immune system / Infection: Antimicrobial action against MRSA, P. aeruginosa, S. aureus, Listeria monocytogenes, and H. pylori documented in laboratory and some clinical settings.
Gastrointestinal system: In vitro and animal studies for gastric ulceration, H. pylori, and dyspepsia; human trials are preliminary or ongoing.
Oropharyngeal / mucous membranes: Small RCT evidence for radiotherapy-induced mucositis using the essential oil as a gargle.
Central nervous system: Preclinical (rat) evidence for anxiolytic/sedative action via GABA-A / benzodiazepine receptor interaction through flavonoids; no human data.
Respiratory system: Historical and traditional use for respiratory ailments and inhalation; no robust modern clinical data.

7. UMF and MGO Grading Systems for Mānuka Honey

The potency of mānuka honey as a supplement or medical product is governed by two interrelated grading systems. The Unique Mānuka Factor (UMF) was originally developed to express the antibacterial activity of mānuka honey in units equivalent to percentage phenol against Staphylococcus aureus in an agar well diffusion assay. With the discovery of MGO and its role in antimicrobial activity, UMF grade is now primarily based on the measured level of MGO: UMF 5+ honey has ≥83 mg/kg MGO, UMF 10+ has ≥263 mg/kg MGO, and UMF 15+ has ≥514 mg/kg MGO.

However, the relationship between UMF grade and therapeutic potency is not perfectly linear. While statistically significant differences in MIC values were detected, the absolute differences in MICs between the three UMF-graded honeys would be considered small by susceptibility testing standards, generally within two-fold dilutions. Mānuka honey exhibited antimicrobial activity against a spectrum of MDR and non-MDR bacterial organisms isolated from wound sites, with greater potency against staphylococcal organisms compared to gram-negative bacteria. In limited sampling, mānuka honey demonstrated significantly greater antimicrobial activity at lower UMF grades compared to UMF 15+ honey, leading researchers to conclude that UMF grade, as an indicator of MGO content and honey quality, may be misleading to the consumer.

8. Dosage Forms and Dosages Reported in Research

Essential Oil (Topical / Aromatherapy)

In the radiotherapy mucositis RCT, the dose was a gargle containing 2 drops of a 1:1 mix of the essential oils of mānuka and kānuka in water.
A product safety study tested 50 healthy human subjects at doses from 0.5% to 100%, finding satisfactory tolerance and deeming the formulation as non-irritant.

Mānuka Honey (Wound Dressing)

Typical medical applications use products rated UMF™ 10+ or MGO 250+.
Formulations include pure honey in sachets for mixing with non-adhesive dressings, and pre-packaged honey dressings (hydrocolloid or alginate backed).

Plant Extract (Preclinical Reference Doses)

In the rat locomotion study, an in vivo sedating effect was observed from the dry extract of a tincture prepared from Leptospermum scoparium using 70% ethanol. Doses of 50 mg and 250 mg of the dry extract per kg body weight were tested. These are animal study doses and should not be extrapolated to human use.

H. pylori Inhibitory Concentrations (In Vitro)

All five clinical H. pylori isolates tested were sensitive to a 20% (v/v) solution of mānuka honey in an agar well diffusion assay. Assessment of the minimum inhibitory concentration showed that all seven isolates had visible growth prevented completely by the presence of 5% (v/v) honey over 72 hours.

9. Safety Considerations

General Tolerability of the Essential Oil

Acute toxicity was not observed (LD50 = 4,612 g/kg body weight) in mice after single oral administration of varying doses (500 mg/kg to 5,000 mg/kg body weight) of a patented formulation containing a mix of Leptospermum scoparium and Kunzea ericoides essential oils. The same formulation did not induce erythema or edema 3 and 7 days after a skin irritation test in epilated rabbits treated with 0.5 g of the product.

No irritation was noted on testing the formulation on rabbit eye mucous membranes. There was no skin sensitization or genetic toxicity after a micronucleus test in TK6 Human lymphoblastoid cells and bacterial reverse mutation test in Salmonella typhimurium and E. coli. The oil is intended for external use and could cause irritation to the eye on direct contact; a patch test is suggested before use.

Methylglyoxal and Diabetic Wound Healing: A Specific Safety Concern

The pronounced antibacterial activity of mānuka honey is due, at least in part, to reactive methylglyoxal (MG), present at up to 100-fold higher concentrations than in conventional honeys. MG is a potent protein-glycating agent and an important precursor of advanced glycation end products (AGEs). MG and AGEs play a role in the pathogenesis of impaired diabetic wound healing and can modify the structure and function of target molecules. This has led to a commentary-level concern that MG in mānuka honey may delay wound healing in diabetic patients.

Infant Botulism Risk (All Honey)

All honey, including mānuka, may contain Clostridium botulinum spores and should not be given to infants under 12 months.

Glycemic Effects of Honey Ingestion

The high sugar content in honey can affect blood glucose. Diabetic patients should limit therapeutic honey intake or select non-sugar preparations such as leaf extracts.

Allergic Reactions

Though relatively rare, some individuals may experience contact dermatitis from essential oils or hives from honey ingestion. Use should be discontinued if a rash or respiratory issues occur.

Potential Drug Interactions

There is a potential synergistic effect with bacitracin, cefadroxil, cephradine, and meropenem, but an antagonistic effect with ofloxacin, enoxacin, and sparfloxacin has been reported for the ketonic fraction of L. scoparium.

Medical-Grade vs. Consumer-Grade Honey

The honey used to treat wounds is medical-grade honey, specially sterilized and prepared as a dressing. A jar of mānuka honey from the pantry should not be used as part of first aid.

10. Evidence Limitations and Research Gaps

There are inadequate supportive robust randomized trials and experimental data to fully accept honey as an effective medical product in wound care. While the unique properties of mānuka honey, particularly its methylglyoxal (MGO) content, offer additional antimicrobial benefits warranting further investigation, more rigorous clinical trials and evidence-based guidelines are paramount in establishing honey's role in modern medicine.

The CNS/sedative effects of L. scoparium flavonoids remain at the animal-study stage, with no published human trials. Evidence for antiviral activity (HSV) is entirely in vitro. Gastrointestinal effects, while mechanistically plausible, lack large, well-controlled human outcome trials. The relationship between standardized potency ratings (UMF/MGO) and real-world clinical outcomes is not yet fully resolved, as other contributing factors such as hydrogen peroxide and bee defensin-1 are present in all honey samples at varying levels, both having different mechanisms of action and not always accounted for in comparative studies.

References

Health Conditions

Health conditions that Leptospermum scoparium may help support.

No conditions available.

Body Systems

Body systems that Leptospermum scoparium may help support.

No body systems available.